AAV vectors play a key role in delivery, but their effectiveness depends on intact genomes – truncated or
incomplete ones can compromise results. So how can we help ensure the safety and efficacy of gene therapies?
Leading experts from Agathos Biologics, Niba Labs, and SK pharmteco tackled this question in a recent
roundtable on vector integrity analysis. They explored dPCR-based solutions, multiplex assay challenges and the
role of reference standards in optimizing gene therapy precision. Want the inside scoop? Grab your copy now.